{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:51:40Z","timestamp":1788951100471,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.annonc.2020.12.012","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T01:59:53Z","timestamp":1609293593000},"page":"542-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data\u2606"],"prefix":"10.1016","volume":"32","author":[{"given":"Y.","family":"Di Filippo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-T.","family":"Leccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Brunet-Possenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Arnnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De Quatrebarbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-E.","family":"Stoebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Oriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Allayous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.annonc.2020.12.012_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.annonc.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2020.12.012_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.annonc.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells9010142","article-title":"Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity","volume":"9","author":"Hartman","year":"2020","journal-title":"Cells"},{"issue":"6257","key":"10.1016\/j.annonc.2020.12.012_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.annonc.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2013 viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.annonc.2020.12.012_bib10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2020.12.012_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ejca.2012.08.028","article-title":"Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies","volume":"49","author":"Sergentanis","year":"2013","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2020.12.012_bib12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jid.2017.04.007","article-title":"Association between body mass index, C-reactive protein levels, and melanoma patient outcomes","volume":"137","author":"Fang","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.annonc.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jdv.12515","article-title":"Role of obesity on the thickness of primary cutaneous melanoma","volume":"29","author":"Skowron","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.annonc.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2020.12.012_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s40425-019-0699-5","article-title":"The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients","volume":"7","author":"Donnelly","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.annonc.2020.12.012_bib18","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.12.012_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.012","article-title":"Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients","volume":"108","author":"Ben-Betzalel","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00262-020-02680-y","article-title":"Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"69","author":"Chen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.annonc.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2020.12.012_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-9966-30-21","article-title":"Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production","volume":"30","author":"Amjadi","year":"2011","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdm464","article-title":"Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study","volume":"19","author":"Gogas","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2020.12.012_bib25","doi-asserted-by":"crossref","first-page":"e3073","DOI":"10.1097\/MD.0000000000003073","article-title":"Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma","volume":"95","author":"Oba","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.annonc.2020.12.012_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A\u00a0multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2020.12.012_bib27","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(18)30287-0","article-title":"Body-mass index and metastatic melanoma outcomes","volume":"19","author":"Nabi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2020.12.012_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2020.12.012_bib29","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","author":"Guzman-Prado","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2020.12.012_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342043220X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342043220X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:02:39Z","timestamp":1760335359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342043220X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S092375342043220X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.12.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data\u2606","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}